196 related articles for article (PubMed ID: 24732154)
1. Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo.
Ma T; Sun X; Cui L; Gao L; Wu Y; Liu H; Zhu Z; Wang F; Liu Z
J Nucl Med; 2014 Jun; 55(6):1002-7. PubMed ID: 24732154
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
3. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
4. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
5. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
6. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
Razumienko E; Dryden L; Scollard D; Reilly RM
Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
[TBL] [Abstract][Full Text] [Related]
7. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
8. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
9. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
10.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
11.
Suman SK; Mukherjee A; Pandey U; Chakraborty A; Rakshit S; Tawate M; Sarma HD
Cancer Biother Radiopharm; 2023 Feb; 38(1):38-50. PubMed ID: 36413344
[No Abstract] [Full Text] [Related]
12. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
13. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
[TBL] [Abstract][Full Text] [Related]
15. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
16. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy.
Jung KH; Choe YS; Paik JY; Lee KH
J Nucl Med; 2011 Sep; 52(9):1457-64. PubMed ID: 21849406
[TBL] [Abstract][Full Text] [Related]
18. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]